Renal Parameters for Jardiance (Empagliflozin)
Jardiance can be initiated in adults with eGFR ≥20 mL/min/1.73 m² for cardiovascular and renal protection, though glucose-lowering efficacy diminishes below 45 mL/min/1.73 m² and is not recommended for glycemic control alone (without established cardiovascular disease or risk factors) when eGFR <30 mL/min/1.73 m² 1.
Initiation Thresholds by Indication
For Glycemic Control
- eGFR ≥30 mL/min/1.73 m²: Can initiate for glucose lowering in patients with established cardiovascular disease or cardiovascular risk factors 1
- eGFR <30 mL/min/1.73 m²: Not recommended for glycemic control in patients without established cardiovascular disease or cardiovascular risk factors 1
- Important caveat: Glucose-lowering benefit is minimal at eGFR <45 mL/min/1.73 m² 2, 1
For Cardiovascular and Renal Protection
- eGFR ≥20 mL/min/1.73 m²: Can initiate and continue for cardiovascular and kidney benefits 2, 1
- Continue until dialysis or transplantation even as eGFR declines, as cardiorenal benefits persist independent of glucose-lowering effects 2
- Contraindicated in patients on dialysis 1
For Pediatric Patients (Ages 10-17)
- eGFR ≥60 mL/min/1.73 m²: Required threshold, as patients with eGFR <60 were not enrolled in pediatric trials 1
Dosing Considerations
No dose adjustment is required based on renal function 1. The standard dosing is:
- Start at 10 mg once daily
- Can increase to 25 mg once daily if additional glycemic control is needed and tolerated
This applies across all eGFR ranges where the drug is indicated, as demonstrated in heart failure trials that enrolled patients with eGFR ≥20 mL/min/1.73 m² 1.
Evidence Supporting Use Across eGFR Ranges
The 2025 ADA guidelines emphasize that SGLT2 inhibitors should be continued for cardiovascular and kidney benefit until dialysis or transplantation, even when glucose-lowering efficacy is minimal 2. This recommendation is supported by:
- EMPA-KIDNEY trial: Enrolled patients with eGFR ≥20 mL/min/1.73 m² and demonstrated reduced kidney disease progression (HR 0.72, P<0.001) 3
- CREDENCE and DAPA-CKD trials: Showed renal benefits in patients with eGFR as low as 25-30 mL/min/1.73 m² 3
- The FDA label explicitly states that heart failure studies enrolled patients with eGFR ≥20 mL/min/1.73 m² without dose adjustment 1
Critical Monitoring Points
Expected eGFR Changes
- Acute "dip": Expect a 2-6% decrease in eGFR within the first 2 months of therapy 4, 5
- Chronic benefit: After the initial dip, empagliflozin reduces the rate of eGFR decline by approximately 50% compared to placebo 4
- This initial dip is not a reason to discontinue therapy - it represents hemodynamic changes that are part of the renoprotective mechanism 4, 5
Safety Considerations with Declining Renal Function
As eGFR decreases, monitor more closely for:
- Volume depletion: Risk increases, especially in patients ≥75 years (4.4% with 25 mg dose) 1
- Urinary tract infections: Risk increases with age and renal impairment 1
- Acute kidney injury: Attention to volume status, particularly during illness or fasting 2, 1
When to Discontinue
- Dialysis initiation: Absolute contraindication 1
- Before scheduled surgery: Discontinue 3-4 days prior due to DKA risk 2
- During critical illness or prolonged fasting: Temporary discontinuation 2
Albuminuria is NOT a Barrier
Do not use albuminuria levels to determine whether to initiate empagliflozin 4. The EMPA-KIDNEY trial demonstrated that empagliflozin slowed CKD progression across all albuminuria categories, with an 86% relative reduction in chronic eGFR slope in patients with uACR <30 mg/g 4. This finding directly contradicts older approaches that stratified SGLT2i recommendations by albuminuria status.